Ask AI

TYK2 Inhibition in Plaque Psoriasis: Biologic Rationale and Recent Findings From AAD 2026

Clinical Thought
Clinical Thought Start Activity
This activity is available for 0.25 CME/CE credit(s).

Released: October 01, 2026

Expiration: September 30, 2027

See Activity Collection

TYK2 inhibitors offer a targeted approach to plaque psoriasis by selectively modulating signaling pathways involved in the IL-23/IL-17 axis, which plays a central role in disease pathogenesis. Recent data presented at the AAD 2026 Annual Meeting provide further insight into the potential of TYK2 inhibition in moderate to severe plaque psoriasis. Learn how next-generation TYK2 inhibitors are showing promise for achieving faster and deeper responses compared with deucravacitinib and may further reshape the plaque psoriasis treatment landscape. Then, consider how these emerging data may inform future clinical decision-making.

TYK2 inhibition in plaque psoriasis

Pre Assessment

Assess your current knowledge and clinical approach before beginning your ClinicalThought.
1.

How many people with psoriasis do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which finding from the phase III LATITUDE and ONWARD trials of zasocitinib and envudeucitinib, respectively, provides evidence that clinical responses may continue to deepen beyond the initial 16-week assessment?